<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94"><gtr:id>5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94</gtr:id><gtr:name>Kirkstall Ltd</gtr:name><gtr:address><gtr:line1>Unit 3 Aspen Court</gtr:line1><gtr:line2>Aspen Way</gtr:line2><gtr:line3>Centurion Business Park</gtr:line3><gtr:postCode>S60 1FB</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A5739A5-B58F-47C1-B425-94267E91DEE1"><gtr:id>5A5739A5-B58F-47C1-B425-94267E91DEE1</gtr:id><gtr:name>Technology Strategy Board</gtr:name><gtr:address><gtr:line1>Block B, Floor 1</gtr:line1><gtr:line2>North Star House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94"><gtr:id>5362E4F8-F47B-4B62-B8EE-FEEDB4BD2C94</gtr:id><gtr:name>Kirkstall Ltd</gtr:name><gtr:address><gtr:line1>Unit 3 Aspen Court</gtr:line1><gtr:line2>Aspen Way</gtr:line2><gtr:line3>Centurion Business Park</gtr:line3><gtr:postCode>S60 1FB</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/16144CCC-398D-4F7B-9B05-909DC51C070F"><gtr:id>16144CCC-398D-4F7B-9B05-909DC51C070F</gtr:id><gtr:firstName>Sikha</gtr:firstName><gtr:surname>Saha</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D8D542D7-B937-423B-BB10-89F363875AE4"><gtr:id>D8D542D7-B937-423B-BB10-89F363875AE4</gtr:id><gtr:firstName>Gin</gtr:firstName><gtr:surname>Jose</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FM013111%2F1"><gtr:id>AA42FE0D-BB22-49D6-B139-E75CE222246A</gtr:id><gtr:title>14TSB_NAT Neurotox: A novel integrated BBB-brain model for comprehensive drug permeability and toxicity testing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M013111/1</gtr:grantReference><gtr:abstractText>The blood-brain barrier (BBB) is composed of different specialised cell types and regulates exchange of substances between the blood and the brain. There are a large number of diseases including stroke, brain trauma and tumours in which the permeability of the BBB is increased. Conversely, many drugs are unable to cross the BBB to reach the brain making the BBB one of the major obstacles in the treatment of the brain diseases. Proper regulation and maintenance of BBB is, therefore, essential for effective drug delivery to the brain to cure brain diseases and preventing its further damage. In this project we aim to develop a three dimensional in vitro BBB model using the Kirkstall Quasi-Vivo system which allows multiple cell types to be cultured in inter-connected culture chambers and a method of assaying the passage of of potential drugs across the BBB by electrochemical and laser bio-sensors. This in vitro model will be an important tool for investigation of different aspects of BBB function and testing potential drugs for their permeability and toxicity and reducing animal usage in this area. Human cell based models should be more accurate and predictive than animals.</gtr:abstractText><gtr:technicalSummary>The blood-brain barrier (BBB) is a highly organised microvasculature system composed of different cell types including brain endothelial cells, pericytes and astrocytes. Disruption of the BBB results in various brain diseases including stroke and Alzheimer's disease. Understanding of BBB integrity and maintenance is, therefore, essential to developing measures for preventing its disruption and also for effective drug delivery to the brain. Currently, most studies on BBB integrity and damage are performed on in vivo models and the current in vitro models do not reflect the cellular interactions that occur in in vivo, as different BBB cell types are cultured and studied in different types of media. The present project aims to develop a three dimensional (3D) in vitro BBB construct within the Kirkstall Quasi-Vivo culture system, which allows multiple cell types to be cultured in inter-connected chambers. Real time tracking of solutes across the BBB will be undertaken using a novel combination of laser and electrochemical bio-sensor based interrogation. Once developed, this in vitro model will be more accessible than an in vivo animal model for investigation of drug transport across the BBB.</gtr:technicalSummary><gtr:potentialImpactText>Please see the application submitted by the TSB partner</gtr:potentialImpactText><gtr:fund><gtr:end>2016-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>82377</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kirkstall Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Engineering Dept in Leeds, QMUL and Kirkstall Ltd</gtr:description><gtr:id>A024F66F-4366-471A-9CD4-93E54909AF14</gtr:id><gtr:impact>Optimisation of conditions for growing three different types of blood brain barrier cells
Development of scaffolding system for different cell culture together to develop the model
Optimisation of flow rates for each cell to survive
Formulation of a common media to culture three types of cells together
Use of laser and electrochemical sensors to measure permeability of the barrier
Successful measurement of transendothelial electrical resistance confirming the tight junction between endothelial cells</gtr:impact><gtr:outcomeId>56dd93e678f5b8.87583174-1</gtr:outcomeId><gtr:partnerContribution>Kirkstall Ltd provided their system and QMUL provided scaffolds and electrochemical sensors to test. Engineering Dept in Leeds provided laser sensors</gtr:partnerContribution><gtr:piContribution>Develop a blood brain barrier using human primary cells under flow mimicking in vivo situation</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BLDE University, India</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5C47C4E1-3EBF-414C-9956-51CC189953B9</gtr:id><gtr:impact>Delivered a talk to 150 undergraduate students
Delivered a seminar to approx. 200 academics/ professionals</gtr:impact><gtr:outcomeId>56dd9e7c217030.16775365</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC project grant</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>44193816-A01C-4D48-BFD9-CD7E05E6D61B</gtr:id><gtr:outcomeId>56dd9920d4e0e8.05661552</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings have been used for further grant funding and for publication
The Kirkstall Ltd have used the findings for commercialisation, business plan and setting up meetings with pharmaceutical companies</gtr:description><gtr:id>1B9623EB-B5AD-4C47-9D8D-77C3DD4A43BA</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56dda1a6405b03.12674695</gtr:outcomeId><gtr:sector>Education</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>A blood brain barrier using human primary cells under flow mimicking in vivo situation has been developed</gtr:description><gtr:exploitationPathways>The finding can be used by academics for understanding transport mechanisms through the blood brain barrier in health and diseases and also by the pharmaceutical companies for drug delivery and toxicity testing</gtr:exploitationPathways><gtr:id>627143F2-CD1E-4F03-A55D-170D1E533CDA</gtr:id><gtr:outcomeId>56dda2d127f0b1.18122851</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Developed a blood brain barrier model under flow</gtr:description><gtr:id>5ABA2F13-0EA0-433A-88C7-1507AFB9CC62</gtr:id><gtr:impact>Developed new grant applications</gtr:impact><gtr:outcomeId>56dd9efc759422.00031448</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>BBB model</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DB636D31-1BF1-4A01-ABA6-9E14ACA8B7BD</gtr:id><gtr:title>The theoretical molecular weight of NaYF:RE upconversion nanoparticles.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5a1c315a40279ebd60c6280bedbc309"><gtr:id>e5a1c315a40279ebd60c6280bedbc309</gtr:id><gtr:otherNames>Mackenzie LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa7b4d0d2aab9.69807488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DCAAAC4-C9B9-49A7-B779-10C89D8950CA</gtr:id><gtr:title>Photoluminescence intensity ratio of Eu-conjugated lactates-A simple optical imaging technique for biomarker analysis for critical diseases.</gtr:title><gtr:parentPublicationTitle>Journal of biophotonics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcca4989cabfd82979483ccb1bc6c9be"><gtr:id>dcca4989cabfd82979483ccb1bc6c9be</gtr:id><gtr:otherNames>Kakkar T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1864-063X</gtr:issn><gtr:outcomeId>5aa7b48e6b4356.02063072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F974BE13-9F29-47E8-AB26-567E7B9A4B2E</gtr:id><gtr:title>A novel method to create an In vitro dynamic blood brain barrier model</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c8bb9fb95f2a9665aae489616b726b"><gtr:id>40c8bb9fb95f2a9665aae489616b726b</gtr:id><gtr:otherNames>Miranda-Azpiazu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c80264208396.20258677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2F102EC-1A45-479C-802D-25683FC14BC7</gtr:id><gtr:title>A three dimensional (3D) human in vitro blood-brain barrier (BBB)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c8bb9fb95f2a9665aae489616b726b"><gtr:id>40c8bb9fb95f2a9665aae489616b726b</gtr:id><gtr:otherNames>Miranda-Azpiazu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c801c71b50a0.88633127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B10C3345-2FE4-4750-9476-3787FF7BBB50</gtr:id><gtr:title>A novel in vitro 3D blood brain barrier for comprehensive drug permeability and toxicity testing</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c8bb9fb95f2a9665aae489616b726b"><gtr:id>40c8bb9fb95f2a9665aae489616b726b</gtr:id><gtr:otherNames>Miranda-Azpiazu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56e009d5c4a909.46248203</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/M013111/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>A442BF36-F335-483E-9282-F3BB48AC2C47</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Cell biology</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>BD108981-2A72-4C45-AAC2-425461EB90BE</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomaterials</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>D16FDB98-8CBA-4298-8ACD-955DF734E7F5</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Cells</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>73EF98E1-3FA8-46A0-BE46-00AE16C7D999</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Communication &amp; signalling</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>DDA3AC5B-B4B5-4323-988E-62B85A8966BF</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Receptors</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>